Article Text

Download PDFPDF
Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice

Statistics from


  • Funding OA received grants by the German Research Foundation (DFG), the Hertie Foundation, the Eugène Devic European Network (EU-FP7), German Ministry for Education and Research (BMBF), Schaufler Foundation, and Walter-and-Ilse-Rose Stiftung; and research support by Bayer Schering, Biogen Idec, Novartis and Teva.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles